Levosimendan in pulmonary hypertension and right heart failure


Pulmonary hypertension is a multifactorial disease with a high morbidity and mortality. Right ventricular function is the most important predictor of morbidity and mortality in patients suffering from pulmonary hypertension, but currently there are no approved treatments directly supporting the failing right ventricle. Levosimendan is a calcium sensitizing agent with inotropic, pulmonary vasodilatory, and cardioprotective properties. Given its pharmacodynamic profile, levosimendan could be a potential novel agent for the treatment of right ventricular failure caused by pulmonary hypertension. The aim of this review is to provide an overview of the current knowledge on the effects of levosimendan in pulmonary hypertension and right heart failure.

Read the full article online


Congenital Heart Disease
Pulmonary Arterial Hypertension
Right Heart Failure


Mona Sahlholdt Hansen, Asger Andersen, Jens Erik Nielsen-Kudsk

Published in:

Pulmonary Circulation Vol 8: No 3 cover image

September 2018

Pulmonary Circulation Vol 8: No 3

View this journal

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI